4 completed, 3 withdrawn. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Withdrawn 3 |
Follow BGG492: new trials by email Literature Review of BGG492 trials Research Report on BGG492
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis BGG492, Placebo - Muscle Spasticity Due to Multiple Sclerosis | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-10-01 | 2017-04-20 | |
| A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention BGG492, Placebo - Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-05-01 | 2017-04-20 | |
| Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram - Adrenocortical Adenoma, Endometrial Stromal Sarcomas | Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2014-08-01 | 2016-12-05 |
| Phase II BGG492 Capsule Extension for Partial Epilepsy BGG492 - Partial Onset Seizures | Phase 2 | Completed | Novartis Pharmaceuticals | 56 | 2011-06-01 | 2021-03-05 |
| Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures BGG492, Placebo - Partial Onset Seizures | Phase 2 | Withdrawn | Novartis | 2010-08-01 | 2012-05-01 | |
| Efficacy and Safety of BGG492 in the Treatment of Migraine BGG492, Sumatriptan, Placebo - Migraine | Phase 2 | Completed | Novartis | 75 | 2009-04-01 | 2020-12-17 |
| Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy BGG492, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Novartis Pharmaceuticals | 13 | 2008-10-01 | 2016-09-23 |
Brain Diseases (2) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Adrenocortical Adenoma (1) · Epilepsy, Reflex (1) · Headache (1) · Migraine Disorders (1) · Multiple Sclerosis (1) · Muscle Spasticity (1) · Sarcoma, Endometrial Stromal (1)
Novartis Pharmaceuticals (5) · Novartis (2)
Germany (4) · United States (4) · Hungary (2) · Slovakia (2) · South Korea (2) · Spain (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Estonia (1) · India (1) · Italy (1) · Latvia (1) · Lithuania (1)
2008 (1)